Monopar Therapeutics (MNPR) Operating Leases (2022 - 2026)

Monopar Therapeutics (MNPR) posted Operating Leases of $154920.0 for Q4 2025, up 118.56% sequentially from $70881.0 in Q3 2025.

Monopar Therapeutics (MNPR) Operating Leases (2022 - 2026) Analysis & Trends

Monopar Therapeutics has reported Operating Leases for 2 years, with the latest figure at $154920.0 in Q4 2025.

Quarterly Operating Leases changed N/A year-over-year to $154920.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $154920.0 (changed N/A YoY) and the FY2025 annual result came in at $154920.0, changed N/A from the prior year.
Operating Leases grew to $154920.0 in Q4 2025 per MNPR's latest filing, from $70881.0 in the prior quarter.
Over five years, Operating Leases peaked at $154920.0 in Q4 2025 and troughed at $8408.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Monopar Therapeutics	965.64 Mn	912.88 Mn	-

Download Data